USA - NASDAQ:INTS - US45828J1034 - Common Stock
ChartMill assigns a Buy % Consensus number of 80% to INTS. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-20 | Benchmark | Maintains | Speculative Buy -> Speculative Buy |
| 2025-08-12 | Brookline Capital | Upgrade | Hold -> Buy |
| 2025-01-13 | Alliance Global Partners | Initiate | Buy |
| 2024-11-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-31 | HC Wainwright & Co. | Initiate | Buy |
| 2024-07-11 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2024-05-16 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2024-03-21 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2023-11-14 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2023-08-24 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2023-07-18 | Benchmark | Initiate | Speculative Buy |
11 analysts have analysed INTS and the average price target is 2.98 USD. This implies a price increase of 1139.6% is expected in the next year compared to the current price of 0.24.
The consensus rating for INTENSITY THERAPEUTICS INC (INTS) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.